Liver Biopsy vs Elastography: A Patient's Guide
Plain-English comparison of liver biopsy and elastography for fibrosis staging — what each test involves, the risks, accuracy, and when biopsy is still required.
If you've been told you might need a liver biopsy, you're not alone in feeling anxious about it. For decades, biopsy was the standard way to assess liver fibrosis. Today, non-invasive elastography has replaced biopsy as the first-line test for most patients in Australia. This article explains what each test involves, the risks, and when biopsy is still the right answer.
What a liver biopsy involves
A standard percutaneous liver biopsy is usually done as a day procedure. After local anaesthetic, a needle is passed between the ribs into the liver to take a small sample of tissue. It's quick — minutes — but patients typically spend 4–6 hours under observation afterwards because of the risk of bleeding.
The biopsy sample is sent to a pathologist who looks at the tissue under a microscope and assigns a fibrosis stage (F0–F4) and an inflammation grade. The major limitation: a biopsy samples about 1/50,000 of the liver. Different parts of the liver can have different stages of disease, and sampling error is a real issue.
What elastography involves
Liver elastography uses ultrasound-based technology to measure how stiff your liver is — a proxy for fibrosis. The scan takes 5–15 minutes, you lie on a clinic bed, no needles are involved, and you walk out immediately afterward. Most patients eat normally the morning of the scan (some clinics ask for 2–3 hours fasting).
Elastography measures a much larger volume of the liver than biopsy, which reduces sampling error. The trade-off: it gives you a number (kPa), not a pathology report. For most patients with MAFLD, hepatitis B, or hepatitis C, that number is exactly what's needed.
The risk comparison
Liver biopsy carries a roughly 1–3% rate of significant complications — most commonly bleeding requiring observation, occasionally requiring transfusion or intervention. Pain after the procedure is common. Serious complications are rare but real: bile leakage, pneumothorax, and very rarely death (estimated at 1 in 10,000).
Elastography has effectively zero procedural risk. The only meaningful issue is that scans can fail or be unreliable in some patients (typically those with very high BMI or ascites), in which case a repeat scan — sometimes on a different device — usually resolves the problem.
When biopsy is still the right answer
Despite elastography's dominance, biopsy still has a role. Cases where biopsy is preferred or required include: when elastography results are genuinely ambiguous and clinical decisions hinge on the answer, when autoimmune or drug-induced liver disease needs histological confirmation, before initiating certain treatments where regulators require biopsy-confirmed disease, and in research or clinical trial settings.
For routine MAFLD, hepatitis B, or hepatitis C fibrosis staging, current Australian and international guidelines recommend non-invasive elastography first. Biopsy is reserved for the minority of cases where non-invasive testing cannot give a confident answer.
What to ask your doctor
If a biopsy has been suggested, ask: 'Has elastography been considered, and if not, why?' For most fibrosis-staging questions, elastography is a reasonable first step. If your doctor explains a specific reason biopsy is still needed (autoimmune workup, ambiguous prior testing, clinical trial), the recommendation is appropriate.